新发BRAF V600E突变的小细胞肺癌和对靶向治疗的持久反应：1例报告

IF 3.3 3区医学 Q2 ONCOLOGY

Clinical lung cancer Pub Date : 2025-02-20 DOI:10.1016/j.cllc.2025.02.012

Radhika Kulkarni , Elias Zeine , Bindu Potugari , Shirish Gadgeel , Joseph Montecalvo , Fawzi Abu Rous

{"title":"新发BRAF V600E突变的小细胞肺癌和对靶向治疗的持久反应：1例报告","authors":"Radhika Kulkarni , Elias Zeine , Bindu Potugari , Shirish Gadgeel , Joseph Montecalvo , Fawzi Abu Rous","doi":"10.1016/j.cllc.2025.02.012","DOIUrl":null,"url":null,"abstract":"<div><div><ul><li><span>•</span><span><div>Small Cell Lung Cancer (SCLC) is rare in those without a history of smoking, underscoring the importance of a thorough smoking history assessment.</div></span></li><li><span>•</span><span><div>While rare, targetable genetic alterations can occur in SCLC, necessitating comprehensive molecular profiling in select cases.</div></span></li><li><span>•</span><span><div>Next generation sequencing should be considered for SCLC patients without a smoking history to identify potentially actionable mutations.</div></span></li><li><span>•</span><span><div>When targetable genetic alterations are detected, a trial of therapy with targeted inhibitors is reasonable, albeit with the understanding that outcomes are typically not promising.</div></span></li></ul></div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"26 4","pages":"Pages e306-e310"},"PeriodicalIF":3.3000,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Small Cell Lung Cancer With de novo BRAF V600E Mutation and Durable Response to Targeted Therapy: A Case Report\",\"authors\":\"Radhika Kulkarni , Elias Zeine , Bindu Potugari , Shirish Gadgeel , Joseph Montecalvo , Fawzi Abu Rous\",\"doi\":\"10.1016/j.cllc.2025.02.012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div><ul><li><span>•</span><span><div>Small Cell Lung Cancer (SCLC) is rare in those without a history of smoking, underscoring the importance of a thorough smoking history assessment.</div></span></li><li><span>•</span><span><div>While rare, targetable genetic alterations can occur in SCLC, necessitating comprehensive molecular profiling in select cases.</div></span></li><li><span>•</span><span><div>Next generation sequencing should be considered for SCLC patients without a smoking history to identify potentially actionable mutations.</div></span></li><li><span>•</span><span><div>When targetable genetic alterations are detected, a trial of therapy with targeted inhibitors is reasonable, albeit with the understanding that outcomes are typically not promising.</div></span></li></ul></div></div>\",\"PeriodicalId\":10490,\"journal\":{\"name\":\"Clinical lung cancer\",\"volume\":\"26 4\",\"pages\":\"Pages e306-e310\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2025-02-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical lung cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1525730425000403\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical lung cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1525730425000403","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

•小细胞肺癌（SCLC）在没有吸烟史的患者中很少见，这强调了全面吸烟史评估的重要性。•虽然罕见，但可靶向的遗传改变可能发生在SCLC中，因此需要对特定病例进行全面的分子谱分析。•下一代测序应考虑用于无吸烟史的SCLC患者，以确定潜在的可操作突变。•当检测到可靶向的基因改变时，使用靶向抑制剂进行治疗的试验是合理的，尽管结果通常不太乐观。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Small Cell Lung Cancer With de novo BRAF V600E Mutation and Durable Response to Targeted Therapy: A Case Report

•
Small Cell Lung Cancer (SCLC) is rare in those without a history of smoking, underscoring the importance of a thorough smoking history assessment.
•
While rare, targetable genetic alterations can occur in SCLC, necessitating comprehensive molecular profiling in select cases.
•
Next generation sequencing should be considered for SCLC patients without a smoking history to identify potentially actionable mutations.
•
When targetable genetic alterations are detected, a trial of therapy with targeted inhibitors is reasonable, albeit with the understanding that outcomes are typically not promising.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical lung cancer 医学-肿瘤学

CiteScore

7.00

自引率

2.80%

发文量

159

审稿时长

24 days

期刊介绍： Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer. The main emphasis is on recent scientific developments in all areas related to lung cancer. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.